CHARM Therapeutics

A few weeks ago, we gathered together for the CHARM Therapeutics summer event. This was made even more special as we marked the opening of our new lab at the Babraham Research Campus. The atmosphere was electric, filled with the excitement of our growth and the anticipation of a bright future ahead! 🚀 🚀 🚀 #biotechnology #drugdiscovery #deeplearning

CHARM scientists Abigail Mornement, Amanda Kennedy and Charlotte Barrett are in Barcelona for this year’s EORTC-NCI-AACR (ENA) Symposium on molecular targets and cancer therapeutics, commonly known as the "triple meeting”.   This meeting is a great opportunity to connect with other scientists and industry leaders and will allow engaging discussions on the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology. To learn more: https://lnkd.in/eb6tKDZE #ai #drugdiscovery #cancer #oncology #triplemeeting

Our Machine Learning Engineering Manager, Liam Atkinson, is attending the BioIndustry Association (BIA) #TechBioUK conference taking place today in Kings Place, London. He’s looking forward to hearing about how cutting-edge machine learning techniques are being used to solve drug discovery and R&D challenges.    To learn more: https://lnkd.in/eRB4eJBH     #oncology #cancer #drugdiscovery #deeplearning #AI 

We are immensely proud to announce that our Scientific Co-Founder, Prof. David Baker, has been awarded the 2024 Nobel Prize in Chemistry. Since 2003, Prof. Baker has pioneered the design of novel proteins, creating spectacular protein structures with applications in pharmaceuticals, vaccines, nanomaterials, and sensors. As the Nobel Academy noted, "Life could not exist without proteins. That we can now predict protein structures and design our own proteins confers the greatest benefit to humankind." We extend our warmest congratulations to Prof. Baker on this extraordinary achievement and look forward to the continued impact of his research. https://lnkd.in/eknNuN4C #oncology #cancer #drugdiscovery #deeplearning #AI

We are immensely proud to announce that our Scientific Co-Founder, Prof. David Baker, has been awarded the 2024 Nobel Prize in Chemistry. Since 2003, Prof. Baker has pioneered the design of novel proteins, creating spectacular protein structures with applications in pharmaceuticals, vaccines, nanomaterials, and sensors. As the Nobel Academy noted, "Life could not exist without proteins. That we can now predict protein structures and design our own proteins confers the greatest benefit to humankind." We extend our warmest congratulations to Prof. Baker on this extraordinary achievement and look forward to the continued impact of his research. https://lnkd.in/eknNuN4C #oncology #cancer #drugdiscovery #deeplearning #AI

Fantastic to see that CHARM Therapeutics has been recognised as one of the top emerging startups in life sciences technology by Tracxn.     #oncology #cancer #drugdiscovery #deeplearning #AI

Can AI Solve the Molecule Mysteries that will Unlock Simpler Drug Discovery?   In the latest episode of RBC Capital Markets’ Pathfinders in Biopharma podcast, our CEO, Laksh Aithani, joins host Noël Brown and Clarissa Desjardins, CEO at Congruence Therapeutics, to answer this exciting question.   In this discussion, Laksh shared insights on AI's role in decoding protein-molecule binding. Tune in to explore the cutting-edge intersection of AI and drug discovery.   Listen now: https://lnkd.in/eJBMwHFc   #drugdiscovery #deeplearning #AI #podcast

We are delighted to announce our appointment of Dr Beverley Carr as Chief Business Officer.   Beverley brings a wealth of experience to CHARM, with an impressive career spanning over a decade at GSK and several leading biotechnology companies, most recently Amphista Therapeutics Limited. Her expertise will be instrumental in driving the value of CHARM’s advanced protein-ligand intelligence platform, DragonFold. She will focus on forming strategic collaborations to leverage the platform’s potential, enabling the creation of new medicines by identifying novel molecules against hard-to-drug proteins. A warm welcome to Bev.   To learn more: https://lnkd.in/e-8UxBuN #appointment #ai #deeplearning #drugdiscovery

Our Project Lead, Oncology, Faiz Bilal-Espejo, PhD, PhD, is attending the ESMO - European Society for Medical Oncology congress taking place in Barcelona from 13-17 September. He is looking forward to discussing the latest developments in oncology from the world’s leading cancer researchers.     For more information: https://lnkd.in/eSBEG7fw     #ESMOGI2024 #oncology #cancer #drugdiscovery #deeplearning #AI 

We are proud to announce that Sarah Skerratt, FRSC, our Chief Scientific Officer, has been invited to join the Scientific Advisory Board of C-Further, a pioneering international consortium launched by Cancer Research Horizons and LifeArc dedicated to the discovery and development of novel therapeutics for childhood and young people’s (CYP) cancers. This initiative, involving an initial investment of £28 million from LifeArc and Cancer Research UK (CRUK), aims to remove barriers to the development of targeted therapies for CYP cancers by uniting researchers, clinicians, scientists, and industry. This effort is crucial as paediatric cancers often differ in biology from adult cancers, yet targeted treatment options remain limited. C-Further is launched today at the AACR Special Conference in Cancer Research: Advances in Paediatric Cancer Research. CHARM is honoured that a member of its leadership team is part of this important initiative which aims to make a lasting impact on the future of childhood cancer therapeutics. Sarah’s deep insights and expertise in drug discovery and development will be instrumental in shaping this critical initiative. Congratulations Sarah! #CYPcancers #InnovationInHealthcare #CancerResearch #AACR #appointment